Menu

Recent Interviews

Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


Alison Coutts, Executive Chairman, Memphasys Ltd.

Alison Coutts
Executive Chairman | Memphasys Ltd.
30 Richmond Road, 2140 Homebush West (AUS)

alison.coutts@memphasys.com

+61 2 8415 7300

Memphasys Executive Chairman Alison Coutts on in vitro fertilisation (IVF)


Thomas Soltau, CEO, wallstreet:online capital AG

Thomas Soltau
CEO | wallstreet:online capital AG
Michaelkirchstraße 17/18, 10179 Berlin (D)

service@smartbroker.de

+49 30 27 57 76 464

Smartbroker - wallstreet:online capital AG CEO Thomas Soltau in an interview on the market launch


15. April 2020 | 08:10 CET

BioNTech, Evotec, EXMceuticals - Stocks with potential

  • Health

Health is the most important thing in life. The current protective measures around the globe in connection with the spread of the Corona Virus Covid-19 show how great the fear and helplessness is. Above all, this pandemic has highlighted the extent of the global dependence on China as a supplier of medicines or medical ingredients and protective clothing. Supply chains will get shorter. Individuals and societies will be more focused on health and wellness. In view of the time after the current Corona Crisis it is expected that politics and the economy will reorganize and reposition themselves.

time to read: 1 minutes by Mario Hose


 

Natural medicine for health

EXMceuticals is a young company focused on the extraction of pure medicinal ingredients from the cannabis plant. The listed company has operations in and near Lisbon, Portugal, and plans to supply the enormous European market with high-quality and pure products from there in the future. In the context of the current Corona Crisis and the time after, the team around CEO Jonathan Summers is an ideal platform to serve a product universe that offers people added value based on entirely natural and under-appreciated ingredients.

EXMceutials already has an operational R&D unit for cannabinoids. It is now in the final stages of finishing the detailed design and equipment specification for an EU-GMP purification facility that is currently unique in Europe in terms of scale. The various fields of use for cannabis in modern medicine will become increasingly important and offer attractive growth prospects for the company and therefore it's investors.

Corona vaccine from 2021

BioNTech has been one of the most discussed companies in connection with the development of a vaccine for the prevention of the spread of Covid-19 for several weeks now. The German company works in cooperation with the pharmaceutical giant Pfizer. The vaccine is expected to be available in a high number of doses in 2021. Pfizer is financing the development of the vaccine and BioNTech will subsequently refund 50% of the costs from the expected revenues. The target markets for the vaccine will be Europe and the USA.

Medical innovation service provider

Evotec is active in the research and development of active ingredients. The main focus is on gene therapy. The company develops new technologies and applies them to access more precise and effective drugs. Evotec cooperates with renowned partners around the globe in early phases to increase efficiency in the development of active ingredients as an external innovation service provider. According to Evotec, quality and speed are at the forefront of its collaboration with customers.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold shares in the aforementioned companies and that there may therefore be a conflict of interest. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

14. May 2020 | 13:11 CET

BioNTech, EXMceuticals, Shop Apotheke Europe, Symrise - Shares gaining momentum

  • Health

The easing of measures to contain the Corona Pandemic will be further extended and, in parallel, companies and their employees will be able to increase personal communications again. However, the curfew phase was also used for strategic decisions and developments, as investors can see from announcements in recent weeks. The situation represents a crisis for many people, but it is also an opportunity for change and a new beginning. Market participants have learned in recent months that dependence on China leads to many bottlenecks and global diversification is therefore necessary. Anyone who wants to be part of it must have the right shares in their portfolio.

Read

16. April 2020 | 07:55 CET

Johnson & Johnson, Memphasys, Procter & Gamble - for a better life

  • Health

Good health is a valuable possession. Small and large companies around the globe are engaged in research and development to make people's lives easier or better through modern and innovative products and solutions. The consumer goods and pharmaceutical sectors often offer attractive opportunities for investors to generate a lucrative return. Well-known companies with established brands usually ensure lasting sales. However, promising young companies also use innovations to attract the attention of investors and customers.

Read

17. January 2020 | 13:37 CET

Evotec, Memphasys, MorphoSys - Growth Industry Health

  • Health

He who is healthy has many desires, he who is ill only one. Companies around the globe deal with diseases and special features of nature in order to treat or cure them. In addition to the widespread disease of cancer, there are also topics that are less talked about, but are also a big market. Developments can be of great importance for investors, physicians and the people affected. It can therefore be worthwhile to deal with the variety of topics.

Read